INT259865

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2008
Last Reported 2009
Negated 3
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 2.32
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
AIBL 3
Aibl (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 17 93.20 High High
Arthritis 7 78.96 Quite High
cva 12 5.00 Very Low Very Low Very Low
tolerance 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 108 95.88 Very High Very High Very High
Disease 30 95.66 Very High Very High Very High
Pain 20 93.20 High High
Arthralgia 24 90.00 High High
Myalgia 6 88.80 High High
Metastasis 66 87.12 High High
Breast Cancer 81 86.52 High High
Endometriosis (extended) 24 86.16 High High
Arthritis 1 78.96 Quite High
Cerebral Palsy 38 76.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition to preventing AIBL, as in Z-FAST, there was a significant improvement in DFS for patients receiving immediate ZA vs delayed ZA (HR 0.588; P = 0.0314).46 Reports of a beneficial effect of ZA treatment on disease recurrence in premenopausal women receiving hormonal therapy with goserelin and anastrozole in a different trial,47,48 and a similar emerging benefit in the Z-FAST trial,45 suggest that, in addition to its effective prevention of AIBL, upfront ZA therapy has an antitumor efficacy benefit as well.


Neg (preventing) Gene_expression (preventing) of AIBL in AIBL associated with disease and recurrence
1) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2747391 Disease Relevance 0.77 Pain Relevance 0
The efficacy and safety of concomitant bisphosphonate therapy with ZA to prevent AIBL in patients receiving letrozole has been investigated in two similarly designed trials, Z-FAST (United States) and ZO-FAST (Europe) (Zometa Femara Adjuvant Synergy Trial).These trials randomized patients receiving adjuvant letrozole to either upfront ZA, initiated at randomization and every 6 months, or delayed ZA, initiated with a post-baseline decrease of ?
Neg (prevent) Gene_expression (prevent) of AIBL in AIBL
2) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2747391 Disease Relevance 0.23 Pain Relevance 0
In addition to preventing AIBL, as in Z-FAST, there was a significant improvement in DFS for patients receiving immediate ZA vs delayed ZA (HR 0.588; P = 0.0314).46 Reports of a beneficial effect of ZA treatment on disease recurrence in premenopausal women receiving hormonal therapy with goserelin and anastrozole in a different trial,47,48 and a similar emerging benefit in the Z-FAST trial,45 suggest that, in addition to its effective prevention of AIBL, upfront ZA therapy has an antitumor efficacy benefit as well.


Neg (prevention) Gene_expression (prevention) of AIBL in AIBL associated with disease and recurrence
3) Confidence 0.07 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2747391 Disease Relevance 0.94 Pain Relevance 0
The average of the scores of the domains makes up the disability index, which varies from 0 to 3 points.
Gene_expression (makes) of disability index
4) Confidence 0.02 Published 2008 Journal Health Qual Life Outcomes Section Body Doc Link PMC2631579 Disease Relevance 0.37 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox